Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteersFirst-in-human administration of CPV-104 marks a major step in drug development for the company’s lead compound (Factor H) and in bringing a new medication to patients
Eleva Appoints Donato Spota as Chief Financial OfficerFreiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial Officer (CFO) and Managing Director. Mr. Spota brings to Eleva profound expertise in complementary business areas including strategic finance, investor relations, business development and international capital markets transactions. Danielle Püschel, currently serving as CFO, is appointed as Chief Accounting Officer.
